Although nonviral gene therapy has great potential for use in the lung, the relative lack of cell-specific targeting has limited its applications. We have developed a new approach for cell-specific targeting based on selective nuclear import of plasmids in nondividing cells. Using a microinjection and in situ hybridization approach, we tested several potential DNA sequences for the ability to mediate plasmid nuclear import in alveolar type II epithelial (ATII) cells. Of these, only a sequence within the human surfactant protein C (SP-C) promoter was able to mediate nuclear localization of plasmid DNA specifically in ATII cells but not in other cell types. We have mapped the minimal import sequence to the proximal 318 nucleotides of the promoter, and demonstrate that binding sites for nuclear factor I, thyroid transcriptional factor 1, and GATA-binding protein 6 and the proteins themselves are required for import activity. Using intratracheal delivery of DNA followed by electroporation, we demonstrate that the SP-C promoter sequence will enhance gene expression specifically in ATII cells in mouse lung. This represents a new activity for the SP-C promoter, and thus ATII cell-specific nuclear import of DNA may prove to be a safe and effective method for targeted and enhanced gene expression in ATII cells.
Introduction
The inability to selectively target genes to specific cell types remains a significant limitation of most methods of gene transfer to the lung or any tissue. Although a few approaches have been developed to restrict expression to desired cell types, two means that are routinely used are the regulation of cell entry by cell surface receptorligand interactions to promote cell-specific internalization of the DNA into the cytoplasm, and the use of cell-specific promoters to preferentially drive transcription. In addition, regulation of the site of delivery (for example, luminal vascular delivery of vectors for endothelial cells or airway delivery for the pulmonary epithelium) is also used in vivo to limit gene delivery to desired sites. We have developed a different approach that exploits the mechanisms by which plasmids are transported into the nucleus of nondividing cells. It has been shown that in the absence of mitosis, plasmids are imported into the nucleus in a sequence-specific manner, and we and others have identified several DNA sequences that mediate this nuclear import. [1] [2] [3] [4] [5] [6] The common feature to these DNA nuclear-targeting sequences (DTSs) is that they contain binding sites for transcription factors. As transcription factors, like all proteins, are synthesized in the cytoplasm, they contain nuclear localization signals (NLSs) that interact with the nuclear protein import machinery for transport into the nucleus. If a plasmid containing the transcription factorbinding site within the DTS is present in the cytoplasm, a newly synthesized transcription factor may bind to this site before nuclear import. The NLS import machinery will then bind to the DNA-bound transcription factors and translocate the DNA-protein complex into the nucleus. 7, 8 One sequence that acts as a DTS is the Simian virus 40 (SV40) enhancer that is known to bind to distinct, ubiquitously expressed, transcription factors and mediate plasmid nuclear entry in all cell types tested to date. 1, 3 The other identified DTSs act in a cellspecific manner by binding to a unique set of cell-specific transcription factors, resulting in nuclear import in only those cells in which the transcription factors are expressed. 9 One such sequence that acts in smooth muscle cells only is the smooth muscle g-actin promoter. 4 This promoter is regulated transcriptionally by the complement of positive and negative transcriptional regulators present within smooth muscle cells, including serum response factor (SRF) and Nkx factors, 10, 11 and we have demonstrated that binding of these factors to the DNA are needed for DNA nuclear import activity in cultured smooth muscle cells. 12 Thus, cell-specific gene delivery and expression can be regulated at the level of nuclear import of the vector DNA.
To identify a DNA nuclear import sequence that is active in alveolar type II epithelial (ATII) cells, a cell that makes up roughly 5% of the alveolar surface, mediates much of the fluid balance within the lung, and which probably serves as a progenitor cell for type I cells, the thin cells that line the remainder of the alveoli and are responsible for gas exchange, we screened the transcriptional regulatory elements of several alveolar epithelial cell-specific genes. In this study, we show that the 318-bp fragment of the SP-C proximal promoter acts as a type II alveolar epithelial cell-specific DTS, activity of which is dependent on binding sites for a number of cell-specific transcription factors. In addition, we show that the SP-C promoter when included on a plasmid enhances gene expression specifically in ATII cells in mouse lung.
Results
Human SP-C promoter mediates plasmid nuclear import in MLE-12 cells
To identify a nuclear import sequence that is active in ATII cells, we screened the transcriptional regulatory elements of several ATII cell-specific genes. On the basis of the literature, we chose the minimal sequence that gave cell-specific transcription, with the assumption that these sequences contain binding sites for ATII-specific transcription factors. These promoter sequences included surfactant protein genes A, B, C and D, and a general epithelial cell-specific gene, cytokeratin 8 (Table 1) . These promoter fragments were PCR amplified from human genomic DNA and cloned into the pCRII-TOPO plasmid, which does not contain a DTS or eukaryotic promoter. 3 To assay for nuclear import, the promoter-containing plasmids were microinjected along with rhodaminelabeled bovine serum albumin into the cytoplasm of MLE-12 cells, a transformed mouse alveolar type II epithelial cell line that expresses high levels of surfactant proteins similar to primary type II cells. 13 Cells were fixed at 8 h post-injection and the DNA was visualized using fluorescence in situ hybridization. Cells showing any nuclear rhodamine-labeled bovine serum albumin were not scored, as the injected labeled protein should not have access to the nucleus unless the cells have divided or have been accidentally injected in the nucleus. Immediately after injection, all plasmids showed diffuse staining throughout the cytoplasm (data not shown). By 8 h, all plasmids were still restricted to the cytoplasm except the plasmid carrying the SP-C promoter ( Figure 1 ). When pCR-SPC was injected into the cytoplasm of MLE-12 cells, all of the injected DNA (490%) migrated to the nucleus in 25-30% of the cells showing fluorescent in situ hybridization signal. An additional 20% of the cells with fluorescent signal showed 450% of the DNA in the nucleus (data not shown). By contrast, none of the cells injected with the other promoter-containing plasmids showed any nuclear localization of the plasmids. Similarly, the plasmid backbone of these plasmids (pCR) showed very little (p5%) nuclear localization when the DNA was injected cytoplasmically ( Figure 1 ). As a positive control, the same plasmid backbone containing the SV40 DTS instead of the SP-C promoter (pCR-SV40) was cytoplasmically injected and visualized at 8 h, and this showed nuclear import activity nearly identical to that of the SP-C promoter.
Human SP-C promoter does not mediate plasmid nuclear import in nonalveolar epithelial type II cells
To determine whether the nuclear import activity of the SP-C promoter was restricted to type II cells, the plasmid was microinjected into the cytoplasm of a variety of cell types and localized by in situ hybridization. These included TC7 cells (green monkey kidney epithelium), HeLa cells (human cervical carcinoma), Beas-2B cells (human bronchial epithelium), NIH3T3 cells (fibroblasts) and primary human pulmonary artery smooth muscle cells. In addition, A549 cells, another alveolar type II-like epithelial cell line and freshly isolated primary rat ATII cells were also tested. All of these cells were injected with pCR-SV40 that showed DNA nuclear localization similar to that seen in MLE-12 cells, demonstrating that all of these cell types have the ability to import plasmid DNA into the nucleus in a sequence-specific manner (data not shown). Further, none of the cells showed nuclear localization of the promoter-less plasmid, pCRII-TOPO (data not shown). Although the pCR-SPC plasmid localized entirely to the nucleus in B30% of the MLE-12, A549 and primary rat ATII cells ( Figure 2 ). By contrast, pCR-SPC showed no nuclear localization in the absence of cell division in any of the other cell types, suggesting that the SP-C promoter mediates nuclear import specifically in ATII cells, but not in nontype II cells.
Specific sequences of the human SP-C promoter are required for alveolar epithelial cell-specific nuclear import
To identify which sequences within the human SP-C promoter were required for ATII-specific nuclear import, ATII cell-specific plasmid nuclear import JV DeGiulio et al plasmids containing the large 3.7-kb fragment of the SP-C promoter, as well as several truncations were tested for import activity using microinjection and in situ hybridization strategy. It has been shown that the developmental expression of the human 3.7-kb SP-C promoter mimics that of the endogenous SP-C gene, indicating that the cis-active regulatory elements for cellspecific and developmental expression are located within this region, whereas the 336-bp (À318 to +18) proximal promoter shows ATII cell-specific expression in cultured cells, suggesting that even this short segment maintains control elements for appropriate cell-specific expression. 14, 15 Both full-length and the 336-bp proximal SP-C promoter showed similar levels of nuclear import activity in MLE12 cells ( Figure 3 ). However, truncation of the promoter to nucleotide À215 abolished DNA nuclear import activity similar to that seen with plasmids lacking any promoter fragment, suggesting that sequences between À215 and À318 are required for DNA nuclear import activity.
Multiple transcription factor binding sites are required for SP-C promoter nuclear import in ATII cell lines
On the basis of the published literature, we mutated several transcription factor-binding sites shown to be important for type II cell-specific transcription, including nuclear factor I (NFI), GATA-binding protein-6 (GATA-6) and thyroid transcriptional factor 1 (TTF-1) to determine which are required for SP-C nuclear import activity. [14] [15] [16] [17] [18] [19] [20] Mutations within the TTF-1 and GATA-6 sites reduced nuclear import activity to background levels (that is, similar to the promoter-less pCRII-DDTS plasmid), as did mutation of the NFI-binding site located at nucleotide position À200 ( Figure 3 ). Interestingly, mutations within the two other NFI-binding sites (located at nucleotide positions À300 and À82) retained B75% nuclear import activity when compared with the wild-type promoter sequence. In combination with the deletion analysis, these results suggest that the region between À219 and À82 are required for DNA nuclear import activity and further that NFI, TTF-1 and GATA-6, which bind in this region, have a role in the ATII-specific DNA nuclear import.
TTF-1, NFIA and GATA-6 are required for SP-C nuclear import activity in MLE-12 cells
To determine whether NFI, TTF-1 and GATA-6 do indeed have a role in the nuclear import of plasmids containing the SP-C promoter, levels of these factors in MLE-12 cells were reduced using small interfering RNA (siRNA) and nuclear import of pCR-SPC was evaluated. As the timing and efficacy of siRNA-mediated reduction of proteins varies for each individual protein, cells were transfected with siRNAs and the window of greatest protein reduction was determined by western blotting (Figure 4a ). Cells treated with TTF-1 siRNA were tested ATII cell-specific plasmid nuclear import JV DeGiulio et al for import activity 48 h after siRNA transfection, whereas cells treated with NF1A or GATA-6 siRNAs were subsequently microinjected at 72 h post-transfection. In all cases, siRNA treatment resulted in 490% reduction of the various transcription factors (Figure 4a ). Knockdown of TTF-1, NFIA or GATA-6 resulted in a substantial inhibition of SP-C nuclear import, whereas treatment of cells with a control, nontargeting siRNA did not affect the level of nuclear import compared with untreated cells (Figure 4b ). Taken together with the DNA mutagenesis studies, these results demonstrate that these three factors are required for the nuclear import of SP-C DTS-containing plasmids.
Use of the SP-C promoter DNA-targeting sequence enhances transgene expression specifically in ATII cells in vivo
To assay the nuclear import activity of the SP-C promoter in vivo, we constructed plasmids that express nucleartargeted yellow fluorescent protein (YFP nuc ) under the control of the cytomegalovirus (CMV) promoter, and which contain or lack the 336-bp SP-C promoter/DTS downstream of YFP. The SP-C promoter was placed downstream of the expression cassette to minimize the transcriptional effects of the SP-C promoter and to isolate its nuclear import activity. Plasmids were delivered through the airways to the lungs of mice using transthoracic electroporation, ventilated briefly after electroporation and killed 48 h post-delivery. 21 Nuclear-targeted yellow fluorescent protein was detected in multiple cell types throughout the airways, alveoli and pleura (Figure 5a ). To determine whether there was any preference for delivery and expression in type II cells, they were visualized with an ATII-specific lamellar body protein antibody. Indeed, most of the cells in the parenchyma that expressed YFP nuc also were positive for lamellar body protein staining. On the basis of our cell culture results, we were surprised by the relative lack of specific targeting to type II cells and the amount of cells in the airways and pleura that also expressed gene product. We hypothesized that the unusually high number of airway and pleural YFP nuc -positive cells could be due to cell division in these cells. As YFP nuc is under the transcriptional control of the CMV promoter, if the plasmids are able to reach the nucleus of any cell type during cell division, YFP nuc will be expressed regardless of any DTS activity. To test this hypothesis, two approaches were taken. First, a plasmid lacking any DTS sequence (pCMV-YFP nuc -DDTS) that has been shown to be transcriptionally equivalent to DTS-containing plasmids in dividing cells, but which has very limited expression in nondividing cells and tissues, was delivered to the mice. 3, 22 Large numbers of YFP nucpositive cells were detected in the airways and pleura of mice receiving pCMV-YFP nuc -DTS, but fewer cells were found in the alveoli ( Figure 5 ). This suggests that cell division probably has a role in gene delivery to the lung. Thus, bromo-deoxyuridine (BrdU) incorporation was used to visualize cell division in these animals ( Figure 5 ). BrdU was injected into animals at several time points before and after DNA delivery, and the animals were killed and prepared as described above. Significant numbers of BrdU-positive cells were detected in the airways and the pleura but were scarce in the alveoli, suggesting that significant numbers of cells in the airway and periphery of the lung are actively dividing, whereas the cells in the alveoli are largely quiescent ( Figure 5 ). To quantify enhancement of gene expression, we decided to focus on the effect of the SP-C promoter on gene expression in the nondividing alveolar cells. Fifteen slides per animal were counted spanning the whole lung and each expressing cell type was classified as ATII (positive staining with antibody marker), ATI, airway or non-type I/non-type II cell ( Figure 6 ). These latter cells are present in the alveolus but do not have the flat phenotype of ATI cells and do not stain positively for ATII, macrophage or fibroblast markers (data not shown). Plasmids containing the SP-C promoter/DTS showed statistically significantly more expression in type II cells compared with type I cells (6.80±1.93 vs 3.13 ± 0.80 cells per section, P p0.01). By contrast, equal As the DDTS plasmid is expressed only in dividing cells, these results suggest that the expression from SP-C promoter/DTS plasmids seen in type I and non-type I/ non-type II cells (and B30% of type II cells) is most probably due to cell division. Taken together, these results suggest that the SP-C promoter/DTS enhances gene delivery and expression preferentially in ATII cells.
Discussion
One of the more important requirements for safe and effective gene therapy is the limitation of gene expression to specific cell types. To date, the majority of techniques developed are directed at the transcriptional and cell entry levels. We have shown in previous studies that specific DNA sequences can be included on plasmids to mediate nuclear import in nondividing cells and that this paradigm can be used to promote and/or restrict gene expression in desired cells. 4, 22, 23 In this study, we demonstrate that the human SP-C promoter is a cellspecific DTS that acts in ATII cells. The sequences needed for nuclear import map to the proximal 318 nucleotides of the SP-C promoter, and mutagenesis has revealed that multiple transcription factor-binding sites within this region are required for nuclear import activity. Moreover, after gene transfer to the nondividing cell populations in the lungs of mice, we have shown that the SP-C promoter enhances gene delivery and expression in preferentially in ATII cells. We have proposed a model for ATII-specific plasmid DNA nuclear import based on important transcription factor-binding sites (Figure 7) . On the basis of the requirement of multiple transcription factor-binding sites for nuclear import activity, our results suggest that a multimeric protein complex forms on the promoter to drive transport through the nuclear pore complex through importin-a and/or importin-b, the NLS receptors. 7, 24 Whether inclusion of multiple copies of the SP-C DTS will increase plasmid nuclear import beyond that seen with one copy has not been evaluated, but it would follow that by increasing the number of potential transcription factor-binding sites, the likelihood of forming productive DNA-protein complexes would increase as would nuclear localization of the plasmid. This remains to be seen. Although the nature of the complex is not known, our data indicate it is dependent on a highly specific set of proteins, including NFI, GATA-6 and TTF-1. Thyroid transcriptional factor 1 has been shown to bind to the SP-C promoter and to be an important regulator of SP-C promoter transcription. 15 It also has been shown that TTF-1 binding is required for the activation of the promoters of surfactant protein A and B. 25, 26 According to our data, as the promoters of surfactant protein A and B do not mediate nuclear import in ATII cells, TTF-1 binding alone may not be sufficient to drive plasmid nuclear import.
According to the mutagenesis studies in MLE-12 cells, it seems that the three central sites binding NFI, TTF-1 and GATA-6 are required for SP-C promoter nuclear import activity. The most proximal and distal NFIbinding sites seem to be least important. Although it is unknown why certain sequences act as DTSs whereas others do not, our hypothesis is that certain sequences will bind transcription factors and other proteins in distinct orientations in which their nuclear localization signals are either exposed and accessible to importin-b binding, or masked from this interaction by another protein or the DNA itself. For example, on the basis of the structure of the TTF-1 protein, 27 the NLS is located within the DNA-binding site, which probably renders the NLS inaccessible to the importin machinery when DNA is bound. However, as it has been shown that other factors, such as GATA-6, Transcriptional co-Activator with PDZ binding motif (TAZ), and the NFI proteins directly interact with TTF-1 and synergistically activate the SP-C promoter, 18, 20, 28 it is possible that the NLSs of these other proteins are exposed and thus involved in plasmid nuclear import, whereas TTF-1 acts only as a required scaffold protein.
Controlling gene expression at the level of nuclear import provides several advantages over other strategies. Limitation of transcription using cell-specific promoters is effective in restricting gene expression to specific cell types, yet levels of expression are limited by the endogenous transcriptional control of the given promoter. Using DTSs, any promoter can be used to drive expression of the transgene (provided it is active in these cells), including strong viral promoters like the CMV immediate early enhancer/promoter, long-term expressing promoters, such as the ubiquitin ligase C promoter, 29, 30 or inducible promoters, such as the tet on/off system. 31 In this way, it is possible to use the most transcriptionally suitable promoter to drive transcription while limiting nuclear import through sequence-specific nuclear import of plasmid DNA to desired cell types. Although the utility of this strategy is dependent on targeting cells that are not undergoing active cell division, considering that the vast majority of cells in vivo are either dividing slowly or nondividing, including those of the pulmonary epithelium, this strategy represents a new strategy for cell-specific targeting of gene expression in vivo.
Although we have shown that inclusion of the SP-C promoter on a plasmid will enhance gene transfer and expression preferentially in nondividing ATII cells in the lung, several other cell types also take up and express transgenes from these plasmids. The fact that the vast majority of these other cells are BrdU-positive suggests that they have probably undergone cell division between the time the plasmids were delivered by electroporation and assayed for gene expression 2 days later. We and others have shown that in the presence of cell division, there is no sequence specificity to nuclear localization of plasmids, 3, 32, 33 and as a ubiquitously active CMV promoter is used to drive the YFP nuc transgene, gene expression would be expected in any cell that divides before analysis. However, it is also possible that some of the gene expression seen in non-type II cells may be due to specific nuclear import of the SP-C promoter-containing plasmids in these cells. Indeed, bronchial and large airway columnar epithelial cells express levels of NF1, GATA-6 and TAZ detectable by immunohistochemistry in human lung sections 34 and TTF-1 is expressed in bronchial epithelial and goblet cells as well. 35 Regardless of the mechanism, this highlights the utility, and limitations, of using nuclear import sequences to restrict gene delivery to desired nondividing cells.
Materials and methods

Plasmids
The 5 0 -flanking sequences and promoters for SP-A, SP-B, SP-C, SP-D and cytokeratin 8 were amplified by PCR from human genomic DNA (Promega, Madison, WI, USA; Table 1 ). The SV40 DTS was amplified by PCR from SV40 genomic DNA. Amplified sequences were inserted into the pCRII-TOPO plasmid (Invitrogen, San Diego, CA, USA). The 3.7-kb human SP-C promoter plasmid was a generous gift from Dr J Whitsett (Cincinatti Children's Hospital, Cincinnati, OH, USA). The 215-bp 
Cell culture and microinjection
The A549 (CCL-185), MLE-12 (CRL-2110), HeLa (CCL-13), Beas-2B (CRL-9609), and NIH3T3 (CRL-1658) cell lines were obtained from American Type Culture Collection (Washington DC, USA). The TC7 cells, a sub-line of African Green Monkey kidney epithelium 1, primary cultures of human pulmonary artery smooth muscle cells (Cambrex, East Rutherford, NJ, USA) and rat ATII cells (a generous gift from K Ridge, Northwestern University, Chicago, IL, USA) were also used. All cells were grown on etched glass coverslips in Dulbecco's Minimal Essential Medium containing 10% fetal bovine serum and supplemented with antibiotics and antimycotics. All cells were cytoplasmically microinjected using an Eppendorf Femtojet system (Hamburg, Germany) as described previously. 36 Purified protein-free DNA was suspended in phosphate-buffered saline and injected at a concentration of 0.5 mg ml À1 , which corresponds to approximately 20 000 plasmids injected per cell. Rhodamine-labeled bovine serum albumin (Molecular Probes, Eugene, OR, USA) was co-injected at a concentration of 0.5 mg ml À1 .
In situ hybridization
In situ hybridizations were performed as described using fluorescently labeled probes prepared by nick translation of pCRII-TOPO or pCAT and mounted with 4',6diamidino-2-phenylindole and the antibleaching reagent DABCO 1. Cells were visualized by fluorescence microscopy on a Leica DMRXA2 (Wetzlar, Germany) and images were captured on a Hamamatsu Orca-ER 12 bit, cooled charge-coupled device (CCD) camera (Hamamatsu, Japan) and OpenLab software (Improvision, Lexington, MA, USA). Confocal microscopy on a Zeiss LCM 510-META (Jena, Germany) was used to confirm nuclear localization.
siRNA delivery and knockdown assessment siRNAs against mouse TTF-1 (Catalog # L-041979-01), NFIA (Catalog # L-044168-01) and GATA-6 (Catalog # L-065585-00) were purchased from Dharmacon (Lafayette, CO, USA) and resuspended to a concentration of 20 mm in 1Â siRNA buffer. Cells were counted and approximately 25 000-50 000 cells were plated on glass coverslips in a 12-well plate. After 24 h incubation in antibiotic-free medium, siRNA was transfected at a concentration of 2 mM in antibiotic-and serum-free media with the DharmaFect 1 transfection reagent (Dharmacon). Medium with serum was added after 24 h if extensive cell death was observed. Cells were lysed at 24, 48 and 72 h post-transfection and protein levels were compared with those seen in cells transfected with a nontargeting siRNA, and assayed at each time point by western blot. Thyroid transcriptional factor 1 was detected using the TTF-1 Ab-1 antibody from Lab Vision/Neomarkers (Catalog #MS-699, Fremont, CA, USA). Nuclear factor I was detected using the NF-1 antibody from Santa Cruz Biotechnology (Catalog #SC-870, Santa Cruz, CA, USA). The GATAbinding protein 6 levels were detected using the antihuman GATA-6 goat polyclonal antibody from R&D Systems (Catalog # AF1700, Minneapolis, MN, USA). The time point at which the greatest knockdown was observed was noted and cells were microinjected with the pCRII-SPC promoter plasmid at this optimum time point. Each siRNA time point optimization was repeated three times.
In vivo gene transfer to the lung
Female Balb/c mice (18-22 g) were anesthetized with sodium pentobarbital (50 mg kg À1 body weight; intraperitoneally) and placed in the supine position. An endotracheal tube (20 G angiocath cut at an angle 2 inches from the end) was placed through the vocal cords into the trachea using a guide wire. A solution of 100 ml of pCMV-YFPnuc-SPC or pCMV-YFPnuc-DDTS DNA (1.5 mg ml À1 ) in 10 mM Tris (pH 8.0), 1 mM EDTA and 140 mM NaCl was instilled into the lungs through the catheter using a Hamilton syringe. Immediately afterwards, an electric field was applied across the animal's chest using eight square wave pulses of 10-ms duration each at a field strength of 200 V cm À1 delivered with a BTX ECM 830 electroporator (BTX, San Diego, CA, USA) and pre-gelled pediatric surface electrodes (Medtronic, Minneapolis, MN, USA). After electroporation, mice were mechanically ventilated at a tidal volume of 150 ml (15% total lung capacity) for approximately 1 min or until they recovered spontaneous breathing. The animals were allowed to recover from anesthesia, returned to the vivarium and 48 h later killed by a sodium pentobarbital overdose. Blood was perfused from the body by injection of 1 ml cold phosphatebuffered saline into the right atrium of the heart. Lungs were fixed in vivo by inflating the lung with 2% paraformaldehyde for 1 h, then removed, inflated to total lung capacity with a 50% mixture of OCT (optimal cutting temperature) medium and phosphate-buffered saline, and snap frozen in liquid nitrogen. All experiments were conducted in accordance with institutional guidelines in compliance with the recommendations of the Guide for Care and Use of Laboratory Animals.
Lung immunofluorescence
Frozen thin sections (8 mm) were permeabilized with 0.2% Triton-X 100 and immunostained with goat antimouse lamellar body 180 antibody as a marker for ATII cells (Chemicon International, Temecula, CA, USA). Antibodies were detected using Alexa 555 antimouse secondary antibodies (Molecular Probes). Direct 
BrdU incorporation
Animals were injected with 0.5 ml 2 mg ml À1 BrdU at 24 and 1 h before gene delivery and at 1, 24 and 45 h postdelivery. The lungs were collected at 48 h and processed for frozen thin sections. Bromo-deoxyuridine incorporation was detected using the BrdU In-Situ Detection Kit (BD Biosciences, San Diego, CA, USA).
